Lymphoma: all 5,623 studies
Page 7 of 57. Open to participants first (823), then studies with results posted, then the rest; newest registration first within each.
- IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasRecruitingNCT05365659Phase 1
- A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and LymphomaRecruitingNCT05358379Phase 1/2
- A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）RecruitingNCT05357651Phase 1
- Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System LymphomaNot yet recruitingNCT05347641Phase 2
- A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell LymphomaNot yet recruitingNCT05343377Not applicable
- A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory LymphomaRecruitingNCT05341557Phase 1
- Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT05338931Phase 1/2
- Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System LymphomaRecruitingNCT05334238Phase 3
- Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/LymphomaRecruitingNCT05333302Phase 1
- Long-Term Follow-up StudyEnrolling by invitationNCT05332054
- Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid TumorsRecruitingNCT05320640Phase 1/2
- Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin LymphomaRecruitingNCT05312801Phase 1
- Electronic MonitorIng of Events for dIffuse Large b Cell LYmphomaNot yet recruitingNCT05298293Not applicable
- Dietary and Topical Magnesium Replacement or Supplementation in Patients With LymphomaRecruitingNCT05294367Early Phase 1
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Phase 2
- ZR-CHOP in DLBCL With Specific Gene AbnormalityRecruitingNCT05290337Phase 2
- ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLRecruitingNCT05290090Phase 2
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- Assessment of Early-detection Based on Liquid Biopsy in Lymphoid MalignanciesRecruitingNCT05275036
- Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System LymphomaRecruitingNCT05260619Phase 2
- Lymfit to Improve the Fitness and Quality of Life in Lymphoma SurvivorsRecruitingNCT05257785Not applicable
- Chemoradiotherapy With Targeted Immunotherapy in Pediatric LymphomaRecruitingNCT05253495Phase 2
- Danish Elder Lymphoma Patient Hematopoietic InvestigationRecruitingNCT05245487
- A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's LymphomaRecruitingNCT05244642Phase 3
- Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's LymphomaRecruitingNCT05243693Phase 2
- Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyRecruitingNCT05237986
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaRecruitingNCT05234684Phase 3
- A Registry Study on HIV-related LymphomaRecruitingNCT05231135
- Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)RecruitingNCT05230680Phase 1/2
- REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEsRecruitingNCT05223413Not applicable
- Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05209620Phase 2
- Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
- The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 YearsRecruitingNCT05179733Phase 3
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingNCT05170399Phase 4
- Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid TumorsRecruitingNCT05156203Phase 1
- Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System LymphomaRecruitingNCT05135858Phase 1
- Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular TherapyRecruitingNCT05135351Not applicable
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT05131022Phase 1
- Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05117814Not applicable
- Secondary Central Nervous System Lymphoma Registry - CharitéRecruitingNCT05114330
- A Study of SHR-A1912 for Injection in Patients With B Cell LymphomasEnrolling by invitationNCT05113069Phase 1
- CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesRecruitingNCT05105867Early Phase 1
- Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaRecruitingNCT05099471Phase 2
- A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT05091541Phase 1/2
- PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk FactorsRecruitingNCT05078840
- Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell LymphomaRecruitingNCT05075460Phase 3
- IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingNCT05073250Phase 2
- Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCLRecruitingNCT05054426Phase 3
- CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaRecruitingNCT05054257Phase 1
- Solving Riddles Through SequencingRecruitingNCT05046444
- R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor BurdenRecruitingNCT05040555Not applicable
- Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell LymphomaRecruitingNCT05020392Phase 3
- Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic MalignanciesRecruitingNCT05011045
- Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S TrialRecruitingNCT05006482Phase 3
- CPAP or BiPAP for Motion Mitigation During RadiotherapyRecruitingNCT04986293Not applicable
- Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral TherapyRecruitingNCT04985214
- A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and LymphomaRecruitingNCT04983810Phase 1/2
- The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical StudyRecruitingNCT04957901
- Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting PeriodRecruitingNCT04957693Not applicable
- Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaRecruitingNCT04938297Phase 2
- Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease StatusRecruitingNCT04934930Phase 2
- Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaRecruitingNCT04922567Phase 2
- DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT04920617Phase 2
- Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingNCT04915248Phase 2
- Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLNot yet recruitingNCT04913103Phase 2
- Improving Cognitive Function in Older Adults Undergoing Stem Cell TransplantRecruitingNCT04898790Not applicable
- Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell LymphomaRecruitingNCT04887025Phase 1
- Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical StudyRecruitingNCT04880746Phase 3
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaRecruitingNCT04870944Phase 1/2
- Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell TherapyRecruitingNCT04870853
- Radiation Free Chemotherapy for Early Hodgkin LymphomaRecruitingNCT04866654Phase 2
- A Phase I/II Study of Diffuse Large B-cell LymphomaNot yet recruitingNCT04856137Phase 1/2
- Avo In R/R And Previously Untreated MCLRecruitingNCT04855695Phase 1/2
- A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CTRecruitingNCT04843267Phase 2
- Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT04838652Phase 2
- Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaRecruitingNCT04837859Phase 2
- MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular LymphomaRecruitingNCT04834024Phase 3
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT04830137Phase 1
- Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)RecruitingNCT04824950Not applicable
- Phase Ib Clinical Study of KeynatinibRecruitingNCT04807881Phase 1
- DALY II USA/ MB-CART2019.1 for DLBCLRecruitingNCT04792489Phase 2
- RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCTRecruitingNCT04776265
- Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaRecruitingNCT04737889Phase 2
- Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell LymphomaRecruitingNCT04736914Phase 2
- Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell LymphomaRecruitingNCT04715217Phase 1/2
- Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st LineRecruitingNCT04670029Phase 3
- A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's LymphomaRecruitingNCT04666168Not applicable
- A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT04665063Not applicable
- Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCLNot yet recruitingNCT04659434Phase 2
- National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
- First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)RecruitingNCT04638790Phase 3
- PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHLRecruitingNCT04624984Phase 2
- CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Early Phase 1
- CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLRecruitingNCT04588922Phase 1/2
- Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae RegistryRecruitingNCT04587388
- Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT04586478Phase 2
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3